Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.76) by 5.68 percent. This is a 21.57 percent increase over losses of $(1.02) per share from the same period last year. The company reported quarterly sales of $1.21 million which missed the analyst consensus estimate of $2.38 million by 49.07 percent. This is a 60.52 percent decrease over sales of $3.08 million the same period last year.